Abstract:SMARCA4 (SWI/SNF-related, matrix-associated, actin dependent regulator of chromatin, subfamily A), an oncogene located at 19p13.2 and encodes the BRG1 protein, is one of the important subunits of SWI/SNF chromatin remodeling complex, which has been considered as a powerful regulator of transcription and DNA repairing, thereby plays an important role in cell cycle control and cell differentiation. [ 1 ] The inactivation of SMARCA4 protein usually leads to a loss of the function of the subunit in SWI/SNF complex and the interruption of ATP energy supply, thus affecting the repositioning or remodeling of the nucleosome of the complex. Transcription cannot be progressed due to the lacking of access to the DNA region that needs to be transcribed, and finally result in the occurrence and progression of various cancer types. [ 2–4 ] SMARCA4 is a novel oncogene that has been reported and named in recent years. In 2015, Le Loarer et al reported a type of highly aggressive thoracic sarcomas, which occurring in young male patients, along with undifferentiated immunophenotype and SMARCA4 loss, and usually presented as an extremely aggressive clinical course and named it as SMARCA4-deficient thoracic sarcoma. [ 5 ] In 2021, the new WHO Classification of Tumors of the Lung, Pleura, Thymus, and Heart adopted the term "SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT)" for the group of tumors that has been previously described as SMARCA4-dTS, which is considered a separate entity from SMARCA4-deficient non-small cell lung cancer (NSCLC). [ 6 ] SMARCA4 mutations has been reported in a variety of cancer types, including uterine sarcoma, small cell carcinoma of the ovary with hypercalcemia, undifferentiated carcinoma of the nasal cavity/sinuses, pleomorphic carcinoma of the gastrointestinal tract, Burkitt lymphoma, and approximately 5% of NSCLC. [ 7 ] It has been reported that patients diagnosed as NSCLC harboring SMARCA4-deficient presented with the characteristics including absence of targetable sensitive mutations, primary resistant to various cytotoxic drugs, and thereby leading to poor prognosis. [ 8 , 9 ] The largest retrospective study which screened 2689 patients with NSCLC for SMARCA4 mutations, conducted in Dana-Farber Cancer Institute has reported that patients with SWI/SNF-mutant NSCLCs had a statistically lower prevalence of concurrent targetable driver mutations ( P < .001), and a significantly shorter median overall survival (mOS) from the time of advanced disease diagnosis ( P = .01), when comparing to SWI/SNF wild-type NSCLC. [ 10 ] Among the 555 SWI/SWF-mutated tumors in that research, the most frequently co-altered genes were presented as TP53, KRAS, and STK11.

P1.03-02 Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer

SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer

1715P the Landscape of SMAD4 Alteration in Chinese Solid Tumor Patients

P2.03-35 Non-Small-Cell Lung Cancer with SMO Gene Variants of Uncertain Significance Share Distinct Molecular Features

Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer

P1.02-059 Molecular Characteristics of SMARCA4 Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients

Additional File 4: of SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients

Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer

P2.03-08 Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer

P1.03-01 Association of APC Mutations with Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer

P3.03-08 Analysis of ESR1 Mutation Spectrum from Non-Small-Cell Lung Cancer in Chinese Patients

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer

Relationship between Expression of TGF-β1, Smad2, Smad4 and Prognosis of Patients with Resected Non-small Cell Lung Cancer

P1.03-04 Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients.

P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer

P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

EP1.03-03 Association Between Molecular Spectrum of EZH2 Variants and Prognosis in Patients with Non-Small-Cell Lung Cancer in Chinese Patients

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

P1.02-049 Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients